• Mink Therapeutics flagged new clinical data on its off-the-shelf iNKT cell therapy agenT-797, with results scheduled for presentation May 14, 2026 at ASGCT 2026.
• Across separate studies in solid tumors and acute respiratory distress syndrome, agenT-797 from same donor manufacturing batch produced disease-appropriate immune effects, supporting a single product strategy across oncology and critical care without genetic engineering.
• Reported outcomes included tumor responses in cancer patients, including a complete metastatic remission in a combination setting, alongside improved survival and pathogen clearance signals in severe ARDS.
• Company also cited a favorable safety profile in both settings, with immune activation occurring without signs of uncontrolled systemic inflammatory toxicity.
• Data were positioned to support a move into randomized Phase 2 testing in acute lung injury under trial C-1300-02, with preliminary readout expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120735PRIMZONEFULLFEED9718287) on May 12, 2026, and is solely responsible for the information contained therein.